Who makes PCV10 fractional dose?

PCV10 fractional dose is developed by Epicentre.

What development phase is PCV10 fractional dose in?

PCV10 fractional dose is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

PCV10 fractional dose

Epicentre · FDA-approved active Biologic Quality 2/100

At a glance

Generic name	PCV10 fractional dose
Sponsor	Epicentre
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV) (PHASE4)
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PCV10 fractional dose CI brief — competitive landscape report
PCV10 fractional dose updates RSS · CI watch RSS
Epicentre portfolio CI